The launch of Celgene’s multiple sclerosis drug, ozanimod, will be delayed after the company failed to submit key information in its application to the Food and Drug Administration (FDA).

The new treatment with ozanimod (also known as zeposia) will benefit over 12,000 adults who suffer from moderate to severe active ulcerative colitis (UC). NICE’s final draft guidance will see ...

It is one of four drugs which have been newly-approved. Ozanimod - Zeposia is manufactured by the company Bristol Myer Squibb. Taken orally once day it provides the advantage of being taken at ...

Ozanimod did not help patients achieve a state where they were no longer experiencing any gastrointestinal symptoms after 12 weeks, compared to a placebo, the company said. Branded as Zeposia ...